Etentamig for Newly Diagnosed Patients
Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2/3
- Enrollment
- 660 patients (estimated)
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), Randomization
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2214
- NCT Identifier
- NCT07095452
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.